AKT1 and neoplasm: Resistance to kinase inhibitors may result from mutations, such as T315I in BCR-ABL, which modify drug binding, activate compensatory pathways (e.g., PI3K/Akt and RAS/MAPK), or are derived from tumor heterogeneity, where distinct tumor subclones develop resistance autonomously.